SAN RAMON, Calif., Jan. 19, 2016 /PRNewswire/ -- Serene Medical Pty. Ltd., a medical device pioneer in RF technology, has recently completed enrollment of its prospective multi-center trial evaluating the effectiveness of the Serene RF System. The Serene clinical trial, which began in February 2015 includes five sites in the U.S. and two sites in Australia. This year long study is designed to evaluate the Serene RF System's ability to effectively improve the appearance of dynamic moderate to severe glabellar lines and sustain long-term aesthetic results. Throughout the trial over 75 patients will serve to validate aesthetic benefits and support the subsequent launch of the Serene RF System which is planned for release in late 2016.
"The excitement and positive responses that have been received to-date from physician partners and their patient base is proof that the aesthetic market is ready for an alternative protocol to what is currently available," says Bankim Mehta, CEO and President of Serene Medical. "With the complete enrollment of the study of the Serene RF System, we look forward to demonstrating how this device, using novel combinations of bi-polar radiofrequency and nerve stimulation technologies, provide long-lasting and toxin free results."
Trevor Moody, Serene Board Member and Managing Director at M.H. Carnegie & Co., with a 25 year career commercializing and funding innovative medical devices, said that the Serene RF system represents an exciting and revolutionary approach to the treatment for glabellar lines. "Physicians and patients will soon benefit from this important new technology."
Serene RF System
Serene Medical has received clearance from the Food and Drug Administration (FDA) to market its Serene Radio Frequency System. Efforts to obtain the CE mark for European commercialization are currently under way. The Serene RF System utilizes a novel, patent protected, radiofrequency technology for locating and treating nerves that cause dynamic wrinkles. The Serene System provides patients immediate visible results and a natural looking, long-duration effect compared to neurotoxin injections. The multicenter study is currently being conducted to document clinical outcomes.
About Serene Medical
Serene Medical is a privately held medical device company with proprietary technology for selectively targeting overactive motor nerves. The first application of Serene technology is planned for the aesthetic market while other therapeutic applications are being explored. Founded in 2010, Serene Medical Pty. Ltd. is a pioneer of RF technology in both the US and Australia and is overseen by a strong board of seasoned entrepreneurs including Bankim Mehta, President and CEO, Trevor Moody, representing M.H. Carnegie and Co. and Elaine Stead, Ph.D. of Blue Sky Venture Capital. Serene holds six issued US device and method patents. Serene continues to file new patent applications maintaining its strong IP position as it commercializes the technology.
For additional information on Serene Medical, please visit www.serenemedical.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
This press release may contain projections or other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release, including any statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. New risks emerge from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995.
SOURCE Serene Medical